阿替普酶静脉溶栓联合依达拉奉注射液治疗急性脑梗死患者的临床效果观察
|
摘要
目的观察阿替普酶静脉溶栓联合依达拉奉注射液治疗急性脑梗死患者的临床效果。方法将医院收治的急性脑梗死患者86例随机分为观察组和对照组,每组43例。对照组给予阿替普酶溶栓治疗,观察组给予阿替普酶静脉溶栓联合依达拉奉注射液治疗。比较2组治疗效果;治疗前、治疗后3 d抽取患者空腹静脉血液,用酶联免疫吸附法测定其肿瘤坏死因子(TNF-α)、IL-8、IL-6、超敏C反应蛋白(hs-CRP)进行比较;记录不良反应发生情况。结果观察组治疗总有效率为95. 35%,高于对照组的69. 77%(P <0. 01);治疗后,2组TNF-α、IL-8、IL-6、hs-CRP水平较治疗前均降低,且观察组上述炎性因子降低幅度大于对照组(P均<0. 01); 2组不良反应总发生率(6. 98%vs9. 30%)比较差异无统计学意义(P> 0. 05)。结论阿替普酶静脉溶栓联合依达拉奉注射液治疗急性脑梗死患者效果显著,可改善血清炎性因子,安全性高,疗效突出。
Objective To observe the clinical effect of Alteplase intravenous thrombolysis combined with edaravone in the treatment of acute cerebral infarction. Methods Eighty-six patients with acute cerebral infarction were randomly divided into observation group and control group,43 cases in each group. The control group was treated with Alteplase thrombolytic therapy,while the observation group was treated with Edaravone on the basis of the control group. The therapeutic effects of the two groups were compared. Fasting venous blood was collected before treatment and on the third day after treatment. TNFa,IL-8,IL-6 and hs-CRP were measured by ELISA and compared. Adverse reactions were recorded in both groups. Results The total effective rate of the observation group was 95. 35%,higher than 69. 77% of the control group( P < 0. 01). After treatment,the levels of TNF-a,IL-8,IL-6 and hs-CRP in the two groups were lower than those in the control group,and the above indexes in the observation group were lower than those in the control group( P < 0. 01). There was no significant difference in the incidence of adverse reactions between the two groups( P > 0. 05). Conclusion Alteplase intravenous thrombolysis combined with Edaravone in the treatment of acute cerebral infarction patients has a significant effect,can improve the level of serum inflammatory factors,high safety,outstanding curative effect.
Objective To observe the clinical effect of Alteplase intravenous thrombolysis combined with edaravone in the treatment of acute cerebral infarction. Methods Eighty-six patients with acute cerebral infarction were randomly divided into observation group and control group,43 cases in each group. The control group was treated with Alteplase thrombolytic therapy,while the observation group was treated with Edaravone on the basis of the control group. The therapeutic effects of the two groups were compared. Fasting venous blood was collected before treatment and on the third day after treatment. TNFa,IL-8,IL-6 and hs-CRP were measured by ELISA and compared. Adverse reactions were recorded in both groups. Results The total effective rate of the observation group was 95. 35%,higher than 69. 77% of the control group( P < 0. 01). After treatment,the levels of TNF-a,IL-8,IL-6 and hs-CRP in the two groups were lower than those in the control group,and the above indexes in the observation group were lower than those in the control group( P < 0. 01). There was no significant difference in the incidence of adverse reactions between the two groups( P > 0. 05). Conclusion Alteplase intravenous thrombolysis combined with Edaravone in the treatment of acute cerebral infarction patients has a significant effect,can improve the level of serum inflammatory factors,high safety,outstanding curative effect.
引文
[1]陈光生,林伯昌,朱伟明,等.丁苯酞软胶囊治疗急性脑梗死的疗效观察[J].现代药物与临床,2017,32(8):1429-1432. DOI:10.7501/j. issn. 1674-5515. 2017. 08. 008.
[2]中医学会神经病学分会脑血管病学组急性缺血脑卒中诊治指南撰学组.中国急性缺血性脑卒中诊治指南2010[J].中华神经科杂志,2010,2(4):50-59.
[3]宜海杰,韩秀平,白利杰,等.依达拉奉联合阿替普酶对急性脑梗死炎性因子的影响[J].现代生物医学进展,2016,16(36):7143-7146. DOI:10. 13241/j. cnki. pmb. 2016. 36. 037.
[4]张莉峰,肖悠美,王爱丽.依达拉奉对急性脑梗死患者rt-PA静脉溶栓后MMP-9表达及出血性转化的影响[J].中国急救医学,2016,36(10):913-917.
[5]左毅,吴婉玉.依达拉奉在急性脑梗死静脉溶栓再灌注损伤中应用效果及保护作用机制研究[J].解放军医药杂志,2017,29(4):65-69. DOI:10. 3969/j. issn. 2095-140X. 2017. 04. 017.
[6]贾媛媛,王成太,王秋茹,等.依达拉奉注射液对急性脑梗死病人神经功能的影响[J].内蒙古医科大学学报,2017,39(4):349-352.
[7]杨丽英,贠莉.依达拉奉注射液联合丁苯酞治疗急性脑梗死的疗效观察[J].药物评价研究,2016,39(4):640-643.
[8]任志学.依达拉奉注射液联合丹参川芎嗪注射液治疗急性脑梗死的临床疗效观察[J].实用心脑肺血管病杂志,2016,24(9):91-93. DOI:10. 3969/j. issn. 1008-5971. 2016. 09. 024.
[9]任瑞鲜,侯俊秀.疏血通注射液联合依达拉奉注射液治疗2型糖尿病伴急性脑梗死的疗效观察[J].中西医结合心脑血管病杂志,2016,14(18):2186-2187. DOI:10. 3969/j. issn. 1672-1349.2016. 18. 036.
[10]程泽君,王文科,邱志宏.舒血宁注射液联合依达拉奉注射液治疗急性脑梗死对血管内皮细胞功能的影响[J].中国中医急症,2016,25(8):1568-1571. DOI:10. 3969/j. issn. 1004-745X. 2016.08. 035.
[11]陶志伟.依达拉奉联合疏血通注射液治疗急性期脑梗死的疗效观察[J].心脑血管病防治,2017,17(2):110-112.
[12]陈庆友,张艳蕉,于熙莹.丁苯酞联合依达拉奉治疗急性脑梗死的临床研究[J].中国临床药理学杂志,2016,32(16):1453-1455. DOI:10. 13699/j. cnki. 1001-6821. 2016. 16. 004.
[2]中医学会神经病学分会脑血管病学组急性缺血脑卒中诊治指南撰学组.中国急性缺血性脑卒中诊治指南2010[J].中华神经科杂志,2010,2(4):50-59.
[3]宜海杰,韩秀平,白利杰,等.依达拉奉联合阿替普酶对急性脑梗死炎性因子的影响[J].现代生物医学进展,2016,16(36):7143-7146. DOI:10. 13241/j. cnki. pmb. 2016. 36. 037.
[4]张莉峰,肖悠美,王爱丽.依达拉奉对急性脑梗死患者rt-PA静脉溶栓后MMP-9表达及出血性转化的影响[J].中国急救医学,2016,36(10):913-917.
[5]左毅,吴婉玉.依达拉奉在急性脑梗死静脉溶栓再灌注损伤中应用效果及保护作用机制研究[J].解放军医药杂志,2017,29(4):65-69. DOI:10. 3969/j. issn. 2095-140X. 2017. 04. 017.
[6]贾媛媛,王成太,王秋茹,等.依达拉奉注射液对急性脑梗死病人神经功能的影响[J].内蒙古医科大学学报,2017,39(4):349-352.
[7]杨丽英,贠莉.依达拉奉注射液联合丁苯酞治疗急性脑梗死的疗效观察[J].药物评价研究,2016,39(4):640-643.
[8]任志学.依达拉奉注射液联合丹参川芎嗪注射液治疗急性脑梗死的临床疗效观察[J].实用心脑肺血管病杂志,2016,24(9):91-93. DOI:10. 3969/j. issn. 1008-5971. 2016. 09. 024.
[9]任瑞鲜,侯俊秀.疏血通注射液联合依达拉奉注射液治疗2型糖尿病伴急性脑梗死的疗效观察[J].中西医结合心脑血管病杂志,2016,14(18):2186-2187. DOI:10. 3969/j. issn. 1672-1349.2016. 18. 036.
[10]程泽君,王文科,邱志宏.舒血宁注射液联合依达拉奉注射液治疗急性脑梗死对血管内皮细胞功能的影响[J].中国中医急症,2016,25(8):1568-1571. DOI:10. 3969/j. issn. 1004-745X. 2016.08. 035.
[11]陶志伟.依达拉奉联合疏血通注射液治疗急性期脑梗死的疗效观察[J].心脑血管病防治,2017,17(2):110-112.
[12]陈庆友,张艳蕉,于熙莹.丁苯酞联合依达拉奉治疗急性脑梗死的临床研究[J].中国临床药理学杂志,2016,32(16):1453-1455. DOI:10. 13699/j. cnki. 1001-6821. 2016. 16. 004.